Company: KROS
Filing Date: 2025-05-09
Form Type: DEFA14A
Source: 0001104659-25-046272
Chunk: 5

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-09
Form: DEFA14A
Chunk 5
---
.

Certain Information Regarding Participants

This communication is neither a solicitation of a proxy or consent
nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees
and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual
Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities
holdings or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 23, 2025, including in the sections
captioned “Compensation Discussion and Analysis,” "Executive Compensation," "Non-Employee Director Compensation," "Transactions with Related Persons
and Indemnification" and "Security Ownership of Certain Beneficial Owners and Management." To the extent that the Company's
directors and executive officers have acquired or disposed of securities holdings since the applicable "as of" date disclosed
in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4
or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents are or will be available
free of charge at the SEC’s website at www.sec.gov.

Contacts

Investor Contact:

Justin Frantz

jfrantz@kerostx.com

617-221-6042

Media Contact:

Mahmoud Siddig / Adam Pollack / Viveca Tress

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449